Volume Alert - INO 10.04 Inovio Pharmaceuticals $INO Hit a

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - INO 10.04 Inovio Pharmaceuticals $INO Hit a high today of 10.35 Closing the day 10:29 at 10.04 -0.96 -8.73% With a day low of 9.51 and a total volume of 1,238,983.

INO Recent Posts: http://investorshangout.com/Inovio-Pharmaceut...INO-56788/

INO Inovio Pharmaceuticals Recent Headline News

Inovio Pharmaceuticals (INO) Stock Drops Following Roche Collaboration Termination
at The Street - 1 hr 16 mins ago
Shares of Inovio Pharmaceuticals (INO) fell Monday after the company announced Roche (RHHVF) had terminated its collaboration, option, and license agreement to develop Inovio's prostate cancer immunotherapy INO-5150.
INO: 9.94 (-1.06)

Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - 1 hr 41 mins ago

BCRX: 10.26 (+0.19), VSR: 2.96 (-0.03), TKMR: 17.10 (+0.69), NNVC: 3.29 (-0.10), INO: 9.94 (-1.06), CMRX: 33.72 (+1.48), APT: 2.89 (-0.03), HEB: 0.27 (unch), SRPT: 15.23 (-0.09), SMED: 4.26 (-0.12), NLNK: 31.48 (+0.94), PLX: 2.05 (-0.04), LAKE: 11.05 (-0.01), NSPH: 0.44 (unch)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST

CADC: 5.65 (+1.39), INO: 9.94 (-1.06), CLDX: 19.13 (+4.97), HAL: 49.60 (-5.48), ROX: 1.86 (-0.12), SNSS: 2.32 (+0.65), DNR: 9.93 (-1.27), DWA: 22.25 (-3.77), GSAT: 2.83 (-0.14), CMGE: 24.88 (-0.72), FOLD: 6.72 (+1.03), BHI: 66.10 (+6.21)

Inovio down on termination of Roche collaboration
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:07AM CST

INO: 9.94 (-1.06)

Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy
PR Newswire - Mon Nov 17, 2:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio. Inovio plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015.
INO: 9.94 (-1.06)

Global Ebola Viral Infections Clinical Trials Report H2, 2014 - Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/wtw3b6/ebola_viral) has announced the addition of the "Ebola Viral Infections Global Clinical Trials Review, H2, 2014" report to their offering. Ebola Viral Infections Global Clinical Trials Review, H2, 2014" provides data on the Ebola Viral Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ebola Viral Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ebola Viral Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Tekmira Pharmaceuticals Corp. - Sarepta Therapeutics, Inc. - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Chimerix, Inc. Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Academy of Military Medical Sciences - University of Oxford For more information visit http://www.researchandmarkets.com/research/wt...bola_viral
INO: 9.94 (-1.06), CMRX: 33.72 (+1.48), SRPT: 15.23 (-0.09), TKMR: 17.10 (+0.69), GSK: 45.98 (+0.24)

Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.55 (+0.44), DHI: 24.53 (+0.15), AMZN: 321.82 (-6.00), TSLA: 254.59 (-4.09), KR: 58.03 (+0.32), SWY: 34.76 (-0.09), CLX: 100.82 (+0.70), XOM: 94.95 (-0.14), FCAU: 12.45 (+0.05), INO: 9.94 (-1.06), WHR: 176.91 (+3.64), T: 35.86 (-0.04), ISIS: 49.07 (+0.06), VALE: 8.84 (-0.03), EOG: 96.63 (-1.53), HAWK: 36.25 (-0.22), SHW: 240.20 (+0.55), VZ: 51.41 (-0.09), TOL: 33.95 (+0.23), REGN: 402.91 (+7.71), KELYA: 15.04 (-0.38), BABA: 114.21 (-0.89)

Inovio to Present at Upcoming Investor Conferences
PR Newswire - Tue Nov 11, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President & CEO, will present a corporate overview at the upcoming Stifel Healthcare Conference, Brean Capital Life Science Conference, and Piper Jaffray Healthcare Conference in New York, NY.
INO: 9.94 (-1.06)

Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 12:14PM CST

INO: 9.94 (-1.06)

Inovio lowers net loss by 77% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:06AM CST

INO: 9.94 (-1.06)

4 Stocks to Look at via Ebola Crisis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 9:43AM CST
Here are four stocks poised to benefit from bringing treatment for the dreaded virus Ebola.
MMM: 158.97 (+0.12), BCRX: 10.26 (+0.19), TK: 54.13 (-0.08), CCL: 41.42 (-0.08), DAL: 43.89 (+0.14), KMB: 113.86 (+1.21), DIS: 90.37 (-0.43), JBLU: 12.44 (-0.16), GSK: 45.98 (+0.24), MAR: 77.45 (-0.51), UAL: 56.84 (+0.74), LUV: 39.39 (+0.44), INO: 9.94 (-1.06), JNJ: 108.29 (+0.13), RCL: 68.56 (-1.01), APT: 2.89 (-0.03)

Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 9.94 (-1.06), SGEN: 35.91 (+0.55), DNDN: 0.16 (+0.05), EXAS: 23.05 (+0.05), ALKS: 52.09 (+0.62)

Inovio Pharmaceuticals beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 5:59AM CST

INO: 9.94 (-1.06)

Inovio posts 3Q loss
Automated Insights - Mon Nov 10, 5:15AM CST
SAN DIEGO (AP) _ Inovio Pharmaceuticals Inc. (INO) on Monday reported a loss of $7.2 million, or 12 cents per share, in its third quarter.
INO: 9.94 (-1.06)

Inovio Pharmaceuticals Reports 2014 Third Quarter Financial Results
PR Newswire - Mon Nov 10, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended September 30, 2014.
INO: 9.94 (-1.06)

Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.78 (+0.30), MNK: 88.44 (+0.33), INO: 9.94 (-1.06)

Inovio reports November 10
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:57AM CST

INO: 9.94 (-1.06)

Inovio Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 10, 2014
PR Newswire - Tue Nov 04, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its third quarter 2014 financial results on Monday, November 10, 2014, at 8:00 a.m. ET. Management will discuss third quarter earnings and expectations for the current and upcoming quarters.
INO: 9.94 (-1.06)

Critical Alerts For Mobileye NV, Schlumberger, Ambarella, Walter Energy and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MBLY, SLB, AMBA, WLT and INO.
AMBA: 48.60 (+0.76), INO: 9.94 (-1.06), WLT: 3.02 (+0.08), MBLY: 47.26 (-0.17), SLB: 96.24 (+0.92)

The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.94 (-1.06), NWBO: 5.49 (-0.30), DNDN: 0.16 (+0.05), GALE: 1.83 (-0.04)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 18

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 15

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 88

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 0

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 16

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 0

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
Ivanti's AI Push Rests on Data, Control and Results

Updated Category News Views 107

Enterprise AI has a nasty habit of sounding brilliant right up until it meets a messy fleet of laptops, phones, patches and permissions. Ivanti’s latest product push is aimed squarely at that unglamorous collision point: giving AI systems governed access to the operational data inside Ivanti Neurons, then keeping humans and pre-set permissions in charge of what happens...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 0

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading

Top 5 Most Recently Viewed Articles

Apple Inc. Faces Class Action Lawsuit Over Securities Fraud

Updated Category News Views 299

Overview of the Class Action Lawsuit Against Apple Inc. The renowned law firm of Kessler Topaz Meltzer & Check, LLP has announced a significant class action lawsuit filed against Apple Inc. The lawsuit, now underway in the United States District Court for the Northern District of California, is focused on claims of securities fraud that impact investors of Apple...

Continue Reading
Oslo Stock Market Experiences Decline Amidst Mixed Performances

Updated Category News Views 102

Oslo Stock Market Experiences Decline The recent trading session on the Oslo Stock Exchange closed with a notable decline, reflecting a complex mixture of performances across various sectors. Generally, the market is affected by fluctuations in key industries such as Media, Transport, and Diversified Financials. Sector Performance Analysis The Oslo OBX index, a critical...

Continue Reading
Doodle's Tender Offer Results: Lexibook Holds Strong Position

Updated Category News Views 210

Doodle's Tender Offer Results Overview In a strategic move within the shares market, the results from Doodle's recent tender offer on Lexibook have been announced. This development is particularly interesting for investors and stakeholders in the electronic leisure products sector. The outcome signifies a notable consolidation of shares following the initiation of...

Continue Reading
Riot Platforms Sees Bullish Signals as Options Trade Surge

Updated Category News Views 283

Riot Platforms Sees Bullish Signals in Options Trading Recent market activities suggest that investors with significant capital are betting on a positive future for Riot Platforms (NASDAQ: RIOT). This turn towards bullish behavior in the stock market highlights the enthusiasm among wealthier traders and institutional investors. The fascinating aspect of this situation is...

Continue Reading
Highlights from Coloplast A/S Annual Meeting and Future Outlook

Updated Category News Views 215

Coloplast A/S Annual General Meeting Insights Coloplast A/S recently hosted its Annual General Meeting, where significant resolutions were discussed and approved. As the company continues to innovate in healthcare, these decisions reflect their commitment to improving the lives of millions. Annual Report Approval One of the main highlights at the meeting was the approval...

Continue Reading